ArticleHaematologica2019
Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01071954 (An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.Blood advances · 2023Trial
- Advances and Clinical Applications of Thrombopoietic Agents.Current medical science · 2026Review
- Treatment of Immune Thrombocytopenia: Contextualization from a Historical Perspective.Hematology reports · 2024Review
- [Maintenance of efficacy and its predictors after discontinuation of eltrombopag in adults with primary immune thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently.Frontiers in cardiovascular medicine · 2023Review
- The Screen of a Phage Display Library Identifies a Peptide That Binds to the Surface ofFrontiers in microbiology · 2022Article
- Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry.Blood advances · 2021Article
- Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.Annals of hematology · 2021Review
- Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia.Yeungnam University journal of medicine · 2021Article
- A Review of Romiplostim Mechanism of Action and Clinical Applicability.Drug design, development and therapy · 2021Review
- Immune Thrombocytopenia in Children: Consensus and Controversies.Indian journal of pediatrics · 2020Review
- The role of romiplostim for pediatric patients with immune thrombocytopenia.Therapeutic advances in hematology · 2020Review
- The child with immune thrombocytopenia: to treat or not to treat, is that still the question?Haematologica · 2019Article
- Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.Blood advances · 2019Review
- Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?Frontiers in immunology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children with immune thrombocytopenia for ≥6 months completing a romiplostim study received weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.